AVEO Oncology Presents Three Posters for
First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC Two...
Source: globenewswire.com
Stay updated with breaking news from Progress Poster Presentation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC Two...